Endocrine

• Launched a survey on the genotyping of thyroid cancer in Europe. A total of 86 practitioners from 18 European Union countries, Switzerland and Turkey responded. Most of them regularly require somatic molecular genotyping. Lack of reimbursement (46.7%), lack of established workflow (46.7%) and lack of access to targeted therapies (40%) were the main reasons not to perform somatic mutations screening.
• Launched a second survey with the Head and Neck Cancer Group on the management of anaplastic thyroid cancer (ATC) in Europe. A total of 94 institutions from 20 countries responded. The results showed that 30 centres evaluate ≥ 5 ATC pts/y with a global incidence >200 pts/y. 80.8% test BRAF. Most clinicians complained about the limitations in drug prescription and only 13.8% have clinical trials ongoing. The results clearly show that ATC still represents a huge unmet need.
• Presented both surveys at the ESMO meeting 2021. Hosted our Group biannual meetings virtually due to Covid-19. Thyroid cancer patients participated for the first time to share about their quality of life and clinical experiences.

This group has been trying to get clinical trials activated, and there is now one trial open to patient recruitment and another large trans-Atlantic collaboration in development with ITOG in the USA.